<DOC>
	<DOCNO>NCT02924272</DOCNO>
	<brief_summary>The purpose study provide continue access ixazomib evaluation long-term safety profile ixazomib .</brief_summary>
	<brief_title>Ixazomib Rollover Study</brief_title>
	<detailed_description>The drug test study call ixazomib . This study look long term safety profile ixazomib participants previously receive tolerated ixazomib Millennium-sponsored clinical study , investigator 's opinion confirm Millennium medical monitor , may benefit continued ixazomib therapy . The study enroll approximately 250 patient . All participant receive ixazomib dose schedule receive parent study experience disease progression , clinical deterioration investigator 's judgment , experience unacceptable toxicity , withdraw consent , pursue alternative therapy , meet study-specified reason discontinuation study drug , ixazomib available participant commercial channel , include reimbursement participant 's indication , whichever sooner . This multicenter , rollover study conduct worldwide . The overall time participate study 7 year . Participants make multiple visit clinic , final visit 30 day last dose ixazomib safety assessment .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>1 . Voluntary write consent must give performance studyrelated procedure part standard medical care . Participants consent enter study within maximum 8 week last dose ixazomib parent study agree Millennium clinician/designee . 2 . Previously treat ixazomib ( exclude comparator placebo participant current treatment ixazomib ) Millenniumsponsored study . Participants eligible enter rollover study : 1 . The parent study close plan close ; 2 . The participant ixazomib monotherapy drug combination another medication , establish his/her parent study ; 3 . In opinion investigator confirm Millennium medical monitor , participant may continue benefit treatment ixazomib ( eg , response therapy stable disease without evidence disease progression ) . 1 . The participant meet criteria treatment discontinuation parent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>